|
gptkbp:instanceOf
|
gptkb:drug
anticonvulsant
|
|
gptkbp:approvalYear
|
1993
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N03AX12
|
|
gptkbp:bioavailability
|
variable, decreases with increasing dose
|
|
gptkbp:brand
|
gptkb:Gralise
gptkb:Horizant
gptkb:Neurontin
|
|
gptkbp:CASNumber
|
60142-96-3
|
|
gptkbp:chemicalClass
|
cyclic GABA analogue
gabapentinoid
|
|
gptkbp:compatibleWith
|
benzodiazepine
opioid
GABA agonist
|
|
gptkbp:contraindication
|
hypersensitivity to gabapentin
|
|
gptkbp:controlledSubstanceStatus
|
varies by country
|
|
gptkbp:discoveredBy
|
gptkb:Parke-Davis
|
|
gptkbp:drugInteraction
|
antacids may reduce absorption
may increase CNS depression with other sedatives
|
|
gptkbp:eliminationHalfLife
|
5–7 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:firstSynthesized
|
1975
|
|
gptkbp:hasMolecularFormula
|
C9H17NO2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
gabapentin
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
binds to α2δ subunit of calcium channels
modulates voltage-gated calcium channels
|
|
gptkbp:metabolism
|
not significantly metabolized
|
|
gptkbp:patentExpired
|
2004
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
adults
children (for epilepsy)
|
|
gptkbp:proteinBinding
|
<3%
|
|
gptkbp:riskOfMisuse
|
yes
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
fatigue
weight gain
drowsiness
ataxia
peripheral edema
visual disturbances
|
|
gptkbp:usedFor
|
gptkb:restless_legs_syndrome
epilepsy
peripheral neuropathy
fibromyalgia
hot flashes
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:GABA
|
|
gptkbp:bfsLayer
|
5
|